Want to see MDCX full AI Analyst Report?
Medicus Pharma Ltd (MDCX) Ratios
Medicus Pharma Ltd Ratios
MDCX's free cash flow for Q2 2026 was $-4.96M. For the 2026 fiscal year, MDCX's free cash flow was decreased by $-5.00 and operating cash flow was $-4.96M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 1.00 | 2.33 | 2.42 | 0.02 | 0.01 |
| Quick Ratio | 1.00 | 2.33 | 2.42 | 0.02 | 0.01 |
| Cash Ratio | 0.88 | 1.81 | 2.20 | 0.02 | 0.01 |
| Solvency Ratio | -2.53 | -4.44 | -4.15 | -0.14 | -0.19 |
| Operating Cash Flow Ratio | -2.29 | -4.44 | -5.32 | -0.08 | -0.14 |
| Short-Term Operating Cash Flow Coverage | -5.79 | -88.09 | 0.00 | -0.69 | -2.17 |
| Net Current Asset Value | $ -133.42K | $ 2.87M | $ 1.11M | $ -12.20M | $ -10.51M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.40 | 0.06 | 0.00 | 5.42 | 8.51 |
| Debt-to-Equity Ratio | -59.15 | 0.10 | 0.00 | -0.13 | -0.06 |
| Debt-to-Capital Ratio | 1.02 | 0.09 | 0.00 | -0.14 | -0.07 |
| Long-Term Debt-to-Capital Ratio | -0.39 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financial Leverage Ratio | -148.94 | 1.80 | 1.70 | -0.02 | -0.01 |
| Debt Service Coverage Ratio | -6.19 | -25.71 | -0.99 | -0.57 | -2.48 |
| Interest Coverage Ratio | -129.91 | -35.21 | -7.94 | -1.86 | -12.49 |
| Debt to Market Cap | 0.15 | 0.00 | 0.00 | 0.30 | 0.03 |
| Interest Debt Per Share | 11.97 | 0.07 | 0.17 | 1.07 | 0.10 |
| Net Debt to EBITDA | 0.19 | 0.34 | 2.93 | -1.08 | -0.30 |
| Profitability Margins | |||||
| Gross Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EBIT Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EBITDA Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Pretax Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Net Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Continuous Operations Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Net Income Per EBT | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| EBT Per EBIT | 138.23% | 99.77% | 112.36% | 172.97% | 142.59% |
| Return on Assets (ROA) | -252.12% | -197.55% | -280.75% | -598.75% | -2617.70% |
| Return on Equity (ROE) | 37549.85% | -355.87% | -478.18% | 13.87% | 19.56% |
| Return on Capital Employed (ROCE) | -14881.51% | -334.69% | -425.57% | 8.02% | 13.72% |
| Return on Invested Capital (ROIC) | -452.42% | -323.43% | -425.57% | 9.17% | 14.65% |
| Return on Tangible Assets | -252.12% | -197.55% | -280.75% | -598.75% | -2617.70% |
| Earnings Yield | -95.92% | -47.72% | -57.64% | -33.09% | -9.64% |
| Efficiency Ratios | |||||
| Receivables Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Payables Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Fixed Asset Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Asset Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Working Capital Turnover Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Sales Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Inventory Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Payables Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Cycle | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -65.89 | -1.07 | -1.20 | -0.55 | -0.18 |
| Free Cash Flow Per Share | -65.89 | -1.07 | -1.20 | -0.55 | -0.18 |
| Dividend Paid and CapEx Coverage Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Capital Expenditure Coverage Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Cash Flow Coverage Ratio | -5.70 | -31.80 | 0.00 | -0.69 | -2.17 |
| Operating Cash Flow to Sales Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Free Cash Flow Yield | -86.13% | -43.84% | -45.10% | -20.67% | -6.79% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -0.78 | -2.09 | -1.73 | -3.02 | -10.38 |
| Price-to-Sales (P/S) Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Price-to-Book (P/B) Ratio | -391.45 | 7.46 | 8.30 | -0.42 | -2.03 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -1.16 | -2.28 | -2.22 | -4.84 | -14.73 |
| Price-to-Operating Cash Flow Ratio | -1.16 | -2.28 | -2.22 | -4.84 | -14.73 |
| Price-to-Earnings Growth (PEG) Ratio | -0.00 | 0.09 | -0.02 | -0.01 | 0.00 |
| Enterprise Value Multiple | -0.86 | -1.75 | -12.78 | -5.47 | -11.30 |
| Enterprise Value | 21.73M | 19.53M | 7.50M | 6.38M | 21.92M |
| EV to EBITDA | -0.86 | -1.75 | -12.78 | -5.47 | -11.30 |
| EV to Sales | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EV to Free Cash Flow | -0.95 | -1.91 | -1.80 | -6.03 | -15.14 |
| EV to Operating Cash Flow | -0.95 | -1.91 | -1.80 | -6.03 | -15.14 |
| Tangible Book Value Per Share | 0.11 | 0.33 | 0.32 | -6.32 | -1.31 |
| Shareholders’ Equity Per Share | -0.20 | 0.33 | 0.32 | -6.32 | -1.31 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Revenue Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income Per Share | -73.38 | -1.16 | -1.53 | -0.88 | -0.26 |
| Tax Burden | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| Interest Burden | 1.01 | 1.00 | 2.00 | 1.45 | 1.06 |
| Research & Development to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Quality | 0.64 | 0.92 | 0.78 | 0.62 | 0.70 |
Currency in USD